Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model

Prostate

Volumn 72, Issue 5, 2012, Pages 514-522

  Bruno, Tullia C ^a   Rothwell, Cristin ^a   Grosso, Joseph F ^a   Getnet, Derese ^a   Yen, Hung Rong ^a   Durham, Nicholas M ^a   Netto, George ^a   Pardoll, Drew M ^a   Drake, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anergy; Clone 4; hemagglutinin; tolerance; TRAMP

Indexed keywords

GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC ANIMAL;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, DUCTAL; CARCINOMA, SMALL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; MALE; MICE; MICE, TRANSGENIC; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 84857505184     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21453     Document Type: Article

References (34)

1. Bogen B, Schenck K, Munthe LA, Dembic Z,. Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncol 2000; 39: 783-788.
2. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B,. Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 1998; 78: 216-222.
3. Schwartz RH,. T cell anergy. Annu Rev Immunol 2003; 21: 305-334.
4. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H,. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-1183.
5. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW, Coryell L, Nelson WG, Pardoll DM, Adler AJ,. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7: 239-249.
6. Shrikant P, Khoruts A, Mescher MF,. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11: 483-493.
7. Bai A, Higham E, Eisen HN, Wittrup KD, Chen J,. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA 2008; 105: 13003-13008.
8. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
9. Vignali DA, Collison LW, Workman CJ,. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523-532.
10. Getnet D, Maris CH, Hipkiss EL, Grosso JF, Harris TJ, Yen HR, Bruno TC, Wada S, Adler A, Georgantas RW, Jie C, Goldberg MV, Pardoll DM, Drake CG,. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol 2009; 182: 4675-4685.
11. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA,. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
12. Ramsdell F, Fowlkes BJ,. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257: 1130-1134.
13. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE,. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 2004; 172: 6074-6079.
14. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH,. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 2007; 179: 993-1003.
15. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP,. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003; 198: 569-580.
16. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, Odermatt B, Speiser DE, Ohashi PS,. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002; 195: 423-435.
17. Whitmore WF, Gittes RF,. Studies on the prostate and testis as immunologically privileged sites. Cancer Treat Rep 1977; 61: 217-222.
18. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG,. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009; 182: 6659-6669.
19. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, DeMarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG,. Cyclophosphamide augments antitumor immunity: Studies in an autochthonous prostate cancer model. Cancer Res 2009; 69: 4309-4318.
20. Mihalyo MA, Hagymasi AT, Slaiby AM, Nevius EE, Adler AJ,. Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate 2007; 67: 536-546.
21. Morgan DJ, Liblau R, Scott B, Fleck S, McDevitt HO, Sarvetnick N, Lo D, Sherman LA,. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol 1996; 157: 978-983.
22. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM,. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-4691.
23. Huang CT, Huso DL, Lu Z, Wang T, Zhou G, Kennedy EP, Drake CG, Morgan DJ, Sherman LA, Higgins AD, Pardoll DM, Adler AJ,. CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol 2003; 170: 3945-3953.
24. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS,. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 1997; 186: 645-653.
25. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M,. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35: 66-75.
26. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA,. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 2007; 178: 1268-1276.
27. Lees JR, Charbonneau B, Hayball JD, Diener K, Brown M, Matusik R, Cohen MB, Ratliff TL,. T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate 2006; 66: 578-590.
28. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De MA, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG,. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007; 117: 3383-3392.
29. Lyman MA, Aung S, Biggs JA, Sherman LA,. A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 2004; 172: 6558-6567.
30. Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA,. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 2005; 174: 2563-2572.
31. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S,. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64: 2205-2211.
32. Huang X, Yang Y,. Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigen. Eur J Immunol 2004; 34: 1351-1360.
33. Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW Jr, Chen L, Pardoll DM, Drake CG,. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007; 110: 186-192.
34. DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T,. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011; 19: 72-85.